Pediatric Nephrology

, Volume 17, Issue 4, pp 302–304 | Cite as

Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy

  • Guido FillerEmail author
  • Rakesh Bhattacharjee
IgA nephropathy Proteinuria ACE inhibitors Losartan Angiotensin II receptor antagonists 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yoshikawa N, Tanaka R, Iijima K (2001) Pathophysiology and treatment of IgA nephropathy in children [review]. Pediatr Nephrol 16:446–457PubMedCrossRefGoogle Scholar
  2. 2.
    Russo D, Pisani A, Balletta MM, DeNicola L, Savino FA, Andreucci M, Minutolo R (1999) Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851–856PubMedCrossRefGoogle Scholar
  3. 3.
    Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM (2001) Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38:18–25PubMedCrossRefGoogle Scholar
  4. 4.
    Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL (1995) Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 123:754–762PubMedCrossRefGoogle Scholar
  5. 5.
    Cattran DC, Greenwood C, Ritchie S (1994) Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23:247–254PubMedGoogle Scholar
  6. 6.
    Mento PF, Wilkes BM (1987) Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 9:III42–48PubMedCrossRefGoogle Scholar
  7. 7.
    Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H (1982) Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4:966–972PubMedCrossRefGoogle Scholar
  8. 8.
    Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A (1993) Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 91:1269–1281PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Phillips MI, Speakman EA, Kimura B (1993) Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 43:1–20PubMedCrossRefGoogle Scholar
  10. 10.
    Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA (1995) Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 43:84–88PubMedGoogle Scholar
  11. 11.
    Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M (1999) A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 10:101–109Google Scholar

Copyright information

© IPNA - International Pediatric Nephrology Association New York, USA 2002

Authors and Affiliations

  1. 1.Department of Pediatrics, Division of NephrologyChildren’s Hospital of Eastern Ontario, University of OttawaOttawaCanada

Personalised recommendations